Health Care & Life Sciences » Pharmaceuticals | Sinovac Biotech Ltd.

Sinovac Biotech Ltd. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
4,514.00
336.00
229.00
3,058.00
36,705.00
36,111
Depreciation, Depletion & Amortization
6,744.00
8,420.00
6,258.00
5,063.00
4,638.00
4,887
Other Funds
860.00
3,571.00
544.00
6,857.00
2,598.00
7,781
Funds from Operations
18,523.00
9,895.00
6,467.00
4,842.00
39,710.00
51,925
Changes in Working Capital
12,947.00
18,542.00
2,079.00
18,744.00
20,046.00
43,982
Net Operating Cash Flow
5,576.00
8,647.00
4,388.00
13,902.00
59,756.00
7,943
Capital Expenditures
5,176.00
11,003.00
5,299.00
12,654.00
11,915.00
Sale of Fixed Assets & Businesses
-
-
882.00
887.00
19.00
Net Investing Cash Flow
5,176.00
11,003.00
4,515.00
11,776.00
11,896.00
Issuance/Reduction of Debt, Net
12,711.00
1,226.00
25,490.00
20,612.00
5,632.00
Net Financing Cash Flow
14,419.00
5,309.00
24,196.00
27,784.00
1,342.00
Net Change in Cash
16,001.00
15,724.00
25,864.00
14.00
50,383.00
Free Cash Flow
400.00
19,650.00
911.00
26,556.00
47,841.00
Deferred Taxes & Investment Tax Credit
2,225.00
162.00
333.00
1,007.00
4,921.00
3,146
Change in Capital Stock
848.00
512.00
750.00
315.00
1,692.00
Exchange Rate Effect
1,182.00
1,383.00
1,541.00
2,092.00
3,865.00
Other Uses
-
-
98.00
9.00
-

About Sinovac Biotech

View Profile
Address
No. 15 Zhi Tong Road
Beijing Beijing 102200
China
Employees -
Website http://www.sinovacbio.com
Updated 07/08/2019
Sinovac Biotech Ltd. is a holding and biopharmaceutical company, which engages in the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases including, without limitation, hepatitis A, hepatitis B, hand foot and mouth disease. It operates through the Mainland China and Hong Kong geographical segments. Its product pipelines include Healive, Bilive, Anflu, PANFLU.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.